Operator

Hello, and thank you for standing by. At this time, I would like to welcome everyone to the Tenaya Therapeutics RIDGE-1 Data Presentation Conference Call. [Operator Instructions] I would now like to turn the call over to Michelle Corral, Vice President of Corporate Communications and Investor Relations. Michelle, please go ahead.

Michelle Corral
Vice President of Investor Relationship & Corporate Communications

Thank you, Tiffany. Hi, everyone, and thank you for joining us today. As you know, I'm Michelle Corral, Head of Investor Relations and Corporate Communications here at Tenaya, and we are excited to share data today from our RIDGE-1 Phase Ib/II clinical trial of TN-401 gene therapy for the potential treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy or ARVC. These data were presented earlier today at the late-breaker oral presentation at the American Society of Gene and Cell Therapy. While the data we are discussing today will be described in full verbally, please note that during the course of today's call, we will be making references to the slides. A PDF file of the slides accompanying this webcast are available on the Tenaya website in the IR section under Events and Presentations.